Company: INDP
Filing Date: 2025-05-14
Form Type: 10-Q
Source: 0001641172-25-010099
Chunk: 34

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-05-14
Form: 10-Q
Item: Part I, Item 1
Chunk 34
---
 terms, and conditions of awards as circumstances may change. This flexibility to adjust the type of compensation
to be granted is particularly important given current economic and world events.

    F-7

A summary of the stock option activity during the
period ended March 31, 2025, is presented in the table below:

 SCHEDULE OF STOCK OPTION ACTIVITY 

    Weighted average  

    Number of  options  
    Exercise  price  
    Remaining  contractual  life  (in years)  
    Intrinsic value 
  
    Outstanding as of January 1, 2025 
     2,887,822  
    $8.06  
     7.6  
    $- 
  
    Granted 
     -  
    $-  
     -  
    $- 
  
    Forfeited and cancelled 
     (625) 
    $-  
     -  
    $- 
  
    Outstanding as of March 31, 2025 
     2,887,197  
    $7.98  
     7.4  
    $- 
  
    Exercisable as of March 31, 2025 
     2,027,405  
    $10.62  
     6.7  
    $- 
  
    Vested and expected to vest as of March 31, 2025 
     2,887,197  
    $7.98  
     7.4  
    $- 

The following table summarizes the total stock-based
compensation expense included in the unaudited consolidated statements of operations for the periods presented:

 SCHEDULE OF STOCK BASED COMPENSATION EXPENSES 

    2025  
    2024 

    For the three months  ended March 31, 

    2025  
    2024 
  
    Research and development 
    $69,662  
    $217,819 
  
    General and administrative 
     171,229  
     556,872 
  
    Total stock-based compensation expense 
    $240,891  
    $774,691 

As of March 31, 2025, total compensation cost not
yet recognized related to unvested stock options was approximately $0.8 million, which is expected to be recognized over a weighted-average